shares jumped in after-hours trading Monday as the Burlington, Mass., company narrowed its GAAP-based losses by two-thirds to $1.4 million, or a penny a share, in the fiscal first quarter and nearly doubled its non-GAAP profits.
Excluding items, the company made $24 million, or 13 cents a share, compared with year-ago income of $11.4 million, or 7 cents a share. Analysts polled by Thomson Financial were expecting a dime a share. Revenue came to $133.8 million on a non-GAAP basis, topping the $129.1 million estimates. The company, which makes speech-recognition software and imaging technology, was gaining 46 cents, or 4.1%, to $11.80.
rose after the insurer swung to a profit in the fourth quarter and in full-year 2006. For the quarter, the Bermuda-based company says it earned $213.6 million, or $3.67 a share, up from a loss of $79.3 million, or $1.42 a share, a year ago. In 2006, it had a $668.3 million profit, or $11.56 a share, compared with losses of $242.6 million, or $4.42 a share, in 2005. Analysts were expecting per-share profits of $2.46 for the quarter and $10.31 for the year. Shares were up $2.50, or 3.7%, to $71.
dropped after the Wayne, Pa., company, which conducts clinical trials for the health care industry, said a recent contract cancellation with $12.8 million remaining slashed its estimated revenue from consolidated backlog to between $38 million and $40 million. The prior forecast range was $52 million to $54 million. Shares were sliding $1.12, or 18%, to $5.10.
announced that the
Securities and Exchange Commission
has begun a probe of trading activity in its securities, specifically requesting records regarding Chief Financial Officer Paul Holt. The Irvine, Calif., maker of health care information systems also issued guidance of 32 cents a share on $38.5 million in sales for the quarter ended Dec. 31. The Street is seeking 30 cents a share on $38.7 million in revenue. Shares were trading down $5.13, or 11.4%, to $40.
lost ground on word the agency overseeing Medicare won't cover the company's implantable vagus nerve-stimulation device for treatment of severe depression, citing insufficient evidence supporting its effectiveness for that purpose. George Parker, interim chief operating officer of Houston-based Cyberonics, called for individuals opposing the decision to "make their voices heard during this public comment period." Shares were falling $2.24, or 9.9%, to $20.31.
met expectations in the fourth quarter, posting income of $7.5 million, or 16 cents a share, up from $6.3 million, or 14 cents a share, a year ago. However, in the next quarter it expects earnings to be between 8 cents and 12 cents a share -- at least 2 cents below expectations. Sales should be between $100 million and $110 million, which would hover at least $1.2 million above Street targets. Still, shares were losing $1.33, or 6.2%, to $20.